CN1960991A - 用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物 - Google Patents

用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物 Download PDF

Info

Publication number
CN1960991A
CN1960991A CNA2005800173175A CN200580017317A CN1960991A CN 1960991 A CN1960991 A CN 1960991A CN A2005800173175 A CNA2005800173175 A CN A2005800173175A CN 200580017317 A CN200580017317 A CN 200580017317A CN 1960991 A CN1960991 A CN 1960991A
Authority
CN
China
Prior art keywords
alkyl
aryl
compounds
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800173175A
Other languages
English (en)
Chinese (zh)
Inventor
P·赫罗尔德
R·马
V·钦克
C·舒马赫尔
M·奎姆巴赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Speedel Experimenta AG
Original Assignee
Speedel Experimenta AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speedel Experimenta AG filed Critical Speedel Experimenta AG
Publication of CN1960991A publication Critical patent/CN1960991A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA2005800173175A 2004-05-28 2005-05-27 用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物 Pending CN1960991A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH915/04 2004-05-28
CH9152004 2004-05-28

Publications (1)

Publication Number Publication Date
CN1960991A true CN1960991A (zh) 2007-05-09

Family

ID=34968588

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800173175A Pending CN1960991A (zh) 2004-05-28 2005-05-27 用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物
CNA2005800170603A Pending CN1968930A (zh) 2004-05-28 2005-05-27 作为芳化酶抑制剂的双环含氮杂环

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005800170603A Pending CN1968930A (zh) 2004-05-28 2005-05-27 作为芳化酶抑制剂的双环含氮杂环

Country Status (10)

Country Link
US (2) US20080076784A1 (enExample)
EP (2) EP1749005A1 (enExample)
JP (2) JP5179174B2 (enExample)
CN (2) CN1960991A (enExample)
AR (2) AR049126A1 (enExample)
BR (2) BRPI0510409A (enExample)
CA (2) CA2568159A1 (enExample)
IL (2) IL179406A0 (enExample)
TW (2) TW200612947A (enExample)
WO (2) WO2005118581A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712589A (zh) * 2009-11-17 2012-10-03 诺瓦提斯公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
CN103958478A (zh) * 2011-11-30 2014-07-30 霍夫曼-拉罗奇有限公司 新双环二氢异喹啉-1-酮衍生物
CN117659075A (zh) * 2023-12-18 2024-03-08 中国科学院兰州化学物理研究所 一种咪唑衍生型柱[5]芳烃手性填料的制备及应用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049126A1 (es) 2004-05-28 2006-06-28 Speedel Experimenta Ag Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
TW200617010A (en) * 2004-07-09 2006-06-01 Speedel Experimenta Ag Organic compounds
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
TW200804284A (en) * 2006-03-31 2008-01-16 Speedel Experimenta Ag Process for preparing 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200813071A (en) 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
DK2319923T3 (en) * 2008-07-24 2014-02-24 Meiji Seika Pharma Co Ltd A PYRIPYROPEN biosynthetic genes
ES2745628T3 (es) * 2008-11-07 2020-03-03 Univ Sheffield Medicamento y método de diagnóstico
DK2426124T3 (da) 2009-05-13 2013-09-30 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af pyripyropene derivater
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
UA111151C2 (uk) 2010-03-01 2016-04-11 Мейдзі Сейка Фарма Ко., Лтд. Спосіб одержання похідних пірипіропену
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
CN105531263B (zh) * 2013-10-17 2019-08-23 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
CN105593212B (zh) * 2013-10-17 2019-06-04 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
IL324432A (en) 2023-05-24 2026-01-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
JPH0670064B2 (ja) 1986-12-08 1994-09-07 三井石油化学工業株式会社 二環性イミダゾ−ル誘導体
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
WO1993015079A1 (en) * 1992-01-27 1993-08-05 Janssen Pharmaceutica N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors
US5763611A (en) * 1992-05-29 1998-06-09 The Procter & Gamble Company Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism
AU6015796A (en) 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US6333335B1 (en) * 1999-07-23 2001-12-25 Merck & Co., Inc. Phenyl-protein transferase inhibitors
JP2001151696A (ja) * 1999-11-22 2001-06-05 Keiko Tanaka アクチニジンから造る腫瘍の増殖ならびに転移抑制酵素と異質なたんぱく細胞の除去剤
CA2429133C (en) * 2000-11-17 2009-08-18 Takeda Chemical Industries, Ltd. Novel imidazole derivatives, production method thereof and use thereof
US7612088B2 (en) 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
US20080076794A1 (en) 2004-05-28 2008-03-27 Peter Herold Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
AR049126A1 (es) 2004-05-28 2006-06-28 Speedel Experimenta Ag Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200813071A (en) 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102712589A (zh) * 2009-11-17 2012-10-03 诺瓦提斯公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
CN102712589B (zh) * 2009-11-17 2015-05-13 诺华股份有限公司 作为醛固酮合酶抑制剂的芳基-吡啶衍生物
CN103958478A (zh) * 2011-11-30 2014-07-30 霍夫曼-拉罗奇有限公司 新双环二氢异喹啉-1-酮衍生物
CN117659075A (zh) * 2023-12-18 2024-03-08 中国科学院兰州化学物理研究所 一种咪唑衍生型柱[5]芳烃手性填料的制备及应用

Also Published As

Publication number Publication date
TW200612947A (en) 2006-05-01
EP1749005A1 (en) 2007-02-07
CN1968930A (zh) 2007-05-23
IL179406A0 (en) 2007-05-15
WO2005118581A1 (en) 2005-12-15
WO2005118540A2 (en) 2005-12-15
IL179408A0 (en) 2007-05-15
AR049126A1 (es) 2006-06-28
JP2008500997A (ja) 2008-01-17
US8680079B2 (en) 2014-03-25
US20070225232A1 (en) 2007-09-27
BRPI0510409A (pt) 2007-10-23
US20080076784A1 (en) 2008-03-27
WO2005118540A3 (en) 2006-02-02
BRPI0511621A (pt) 2008-01-02
AR049125A1 (es) 2006-06-28
CA2568163A1 (en) 2005-12-15
JP2008501000A (ja) 2008-01-17
EP1765777A2 (en) 2007-03-28
JP5179174B2 (ja) 2013-04-10
CA2568159A1 (en) 2005-12-15
TW200616623A (en) 2006-06-01

Similar Documents

Publication Publication Date Title
US8680079B2 (en) Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors
US7612088B2 (en) Heterocyclic compounds and their use as aldosterone synthase inhibitors
JP5165558B2 (ja) アルドステロンシンターゼ阻害剤としての複素環スピロ化合物
JP4980417B2 (ja) アルドステロン合成酵素インヒビターとしての縮合イミダゾール誘導体
CN101421279B (zh) 咪唑化合物
EP1748986B1 (en) Heterocyclic compounds and their use as aldosterone synthase inhibitors
JP5007299B2 (ja) アルドステロンシンターゼ阻害剤としての複素環スピロ化合物
US20100168145A1 (en) Fused imidazole derivatives and use thereof as aldosterone synthase inhibitors
WO2006005726A2 (en) Heterocyclic compounds
US20170304312A1 (en) 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070509